In the past 10 years, a large number of radioligands based on antibodies, mono- and minibodies, and affibodies and nanobodies have been developed and investigated both preclinically and clinically for the imaging of either PD-1 or PD-L1 up- and dysregulation—or both simultaneously—in cancer patients. This evidence concerns the gene PDCD1 and cancer.